Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
GlobeNewswire
*Allschwil, Switzerland, December 11, 2023*
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage..